The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: No effects on VLDL substrate affinity to lipolysis or LDL receptor binding

Atherosclerosis

Volumn 153, Issue 2, 2000, Pages 363-371

  De Man, Frits H A F ^a   De Beer, Femke ^a,b   Van der Laarse, Arnoud ^a   Jansen, Hans ^c   Leuven, Jan A Gevers ^a,b   Souverijn, John H M ^a   Vroom, Ton F F P ^a   Schoormans, Selene C M ^a   Fruchart, Jean Charles ^d   Havekes, Louis M ^a,b   Smelt, Augustinus H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Apolipoprotein C III; Apolipoprotein E; Heparan sulfate proteoglycan; Lipoprotein lipase; Peroxisome proliferator activated receptor

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RECEPTOR BINDING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; BEZAFIBRATE; DOUBLE-BLIND METHOD; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RECEPTORS, LDL; SUBSTRATE SPECIFICITY; UP-REGULATION;

EID: 0034503308     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00409-3     Document Type: Article

References (42)

1. Plasma triglyceride and coronary heart disease
2. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
3. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction
4. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia
5. Plasma glucose and insulin responses to oral glucose in nonobese subjects and patients with endogenous hypertriglyceridemia
6. Heterozygosity for ASN(291)SER mutation in 1 the lipoprotein lipase gene in two Finnish pedigrees: Effect of hyperinsulinemia on the expression of hypertriglyceridemia
7. Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal
8. Prevalence of alleles encoding defective lipoprotein lipase in hypertriglyceridemic patients of French Canadian descent
9. Association of a DNA polymorphism in the apolipoprotein C-III gene with diverse hyperlipidaemic phenotypes
10. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms
11. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration
12. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
13. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins
14. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
15. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
16. Coordinate regulation of the expression of the fatty acid transport protein and acylCoA synthetase genes by PPARalpha and PPARgamma activators
17. Induction of the acyl coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
18. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism
19. Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
20. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
21. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
22. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
23. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
24. Protein measurement with the Folin phenol reagent
25. Apolipoprotein E genotyping on agarose gels
26. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease
27. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycan-bound lipoprotein lipase
28. No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers
29. Separation of plasma lipoproteins by density-gradient ultracentrifugation
30. The metabolism of very low density lipoprotein. I. Preliminary in vitro and in vivo observations
31. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action
32. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment
33. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia
34. Is hypertriglyceridemic very low density lipoprotein a precursor of normal low density lipoprotein?
35. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
36. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism
37. Lipoprotein clearance mechanisms in LDL receptor deficient 'Apo-B48-only' and 'Apo-B100-only' mice
38. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants
39. Low-dose colestipol plus fenofibrate: Effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia
40. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects
41. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase
42. Triglyceride lipases and atherosclerosis